Trial results

$IKT — IKT-001

Inhibikase Therapeutics, Inc. (IKT) IKT-001: trial results in Pulmonary arterial hypertension (PAH), 2027.

Research by Catalyst Intel

The catalyst

"1H 2027 Interim safety readout for Part A of Phase 3 IMPROVE-PAH Study (n=50)"

— Inhibikase Therapeutics, Inc., 8-K filed 2026-09-08 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

IKT-IKT001-2026

Company

Inhibikase Therapeutics, Inc.

Kind

Trial results

Indication

Pulmonary arterial hypertension (PAH)

Window

2027-01-01 – 2027-06-30

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2027-07-30; subscribers get it on the day.